SEC Form 4 · accession 0001209191-16-142706
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac E. Ciechanover
Officer — Chief Executive Officer · Director
Period of report
Sep 22, 2016
Accepted (ET)
Sep 23, 2016 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 22, 2016 | A | 320,000 | $0.00 | A | 549,136 | D | |
| Common StockF2 | holding | — | — | — | 418,578 | I | See Footnote | |
| Common StockF3 | holding | — | — | — | 180,000 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These restricted stock units vest over 4 years, 50% on the 2nd anniversary of the grant date of September 22, 2016 and 25% on the anniversary of the grant date of September 22, 2016 in each of the following years.
- F2Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- F3Shares are held by the Ciechanover 2015 GRAT, of which the Reporting Person is a trustee.